TAKEDA PHARMACEUTICAL CO LTD - 28 Apr 2022 Form 3 Insider Report for HilleVax, Inc. (HLVX)

Role: 10%+ Owner
Signature: /s/ Yoshihiro Nakagawa, Global General Counsel of Takeda Pharmaceutical Company Limited
Issuer symbol: HLVX
Transactions as of: 28 Apr 2022
Net transactions value: $0
Form type: 3
Filing time: 29 Apr 2022, 06:02:17 UTC
Previous filing: 16 Mar 2022
Next filing: 09 May 2022
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
holding	HLVX	Common Stock						500,000	28 Apr 2022	See Explanation of Responses	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
holding	HLVX	Warrant (Right to Buy)							28 Apr 2022	Common Stock	3,500,000	$0.000100	See Explanation of Responses	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Takeda Pharmaceutical Company Ltd's beneficial ownership of the reported securities is comprised of 500,000 shares of Common Stock and a Warrant to purchase 3,500,000 shares of Common Stock; each held by Takeda Vaccines, Inc., an indirect wholly-owned subsidiary of Takeda Pharmaceutical Company Limited. Takeda Vaccines, Inc. is owned directly by Takeda Pharmaceuticals U.S.A., Inc., which is owned directly by both Takeda Pharmaceutical Company Limited (72.70%) and Takeda Pharmaceuticals International AG (27.30%). Takeda Pharmaceuticals International AG is a wholly-owned direct subsidiary of Takeda Pharmaceutical Company Limited.

Content

Takeda Pharmaceutical Company Ltd's beneficial ownership of the reported securities is comprised of 500,000 shares of Common Stock and a Warrant to purchase 3,500,000 shares of Common Stock; each held by Takeda Vaccines, Inc., an indirect wholly-owned subsidiary of Takeda Pharmaceutical Company Limited. Takeda Vaccines, Inc. is owned directly by Takeda Pharmaceuticals U.S.A., Inc., which is owned directly by both Takeda Pharmaceutical Company Limited (72.70%) and Takeda Pharmaceuticals International AG (27.30%). Takeda Pharmaceuticals International AG is a wholly-owned direct subsidiary of Takeda Pharmaceutical Company Limited.